ºÚÁϳԹÏÍø

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ºÚÁϳԹÏÍø News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

WHAT'S NEW

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Oct 17 2019

Full Issue

Eyeing CBD's Booming Popularity In Consumer Marketplace, Pharma Eagerly Chases Success In Lucrative Space

Pharma companies are pumping money into research on drugs that utilize CBD oil in an effort to cash in during the ingredient's boom in consumer popularity. Meanwhile, a look at the benefits and risks of the oil.

Americans are already spending millions on CBD gummies and CBD lotions — but that’s chump change, at least if you ask the pharmaceutical companies betting that a CBD-based prescription medicine will ultimately be far more lucrative. A number of pharmaceutical companies are shepherding their CBD-based products through the lengthy and expensive FDA approval process on exactly that bet — and some are further along than others. (Florko, 10/17)

When it comes to hemp and cannabis, there is much confusion among the public about labels, because of how science and the law define these substances. For the average person, it’s almost like having too many cousins with the same first name. Another source of confusion is that recreational use and medical use of marijuana — though they are different things — are both gaining legal and social acceptance in the United States. (Kanne, 10/16)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ºÚÁϳԹÏÍø
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF